ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells

BACKGROUND: Platinum drugs, including cisplatin, are a frontline therapeutic in ovarian cancer treatment and acquired resistance to these agents is a major contributor to ovarian cancer morbidity and mortality. In this study a novel glycosylation-dependent mechanism for cisplatin resistance is descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz, Matthew J, Swindall, Amanda F, Wright, John W, Sztul, Elizabeth S, Landen, Charles N, Bellis, Susan L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637436/
https://www.ncbi.nlm.nih.gov/pubmed/23578204
http://dx.doi.org/10.1186/1757-2215-6-25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637436/
https://www.ncbi.nlm.nih.gov/pubmed/23578204
http://dx.doi.org/10.1186/1757-2215-6-25

Ejemplares similares